Karyopharm Targets August sNDA Submission for Myelofibrosis Combination Therapy
Event summary
- Karyopharm plans to submit a supplemental New Drug Application (sNDA) in August 2026 for selinexor in combination with ruxolitinib for myelofibrosis under the Accelerated Approval pathway.
- Second quarter 2026 revenue was $33.4 million, with U.S. XPOVIO net product revenue at $30.8 million.
- The Phase 3 SENTRY trial results were presented at ASCO and EHA, demonstrating rapid spleen responses and promising overall survival findings.
- The company reaffirmed full-year 2026 total revenue guidance of $130 million to $150 million.
The big picture
Karyopharm's planned sNDA submission for selinexor in combination with ruxolitinib represents a strategic pivot towards myelofibrosis, a multi-billion-dollar U.S. marketplace with significant unmet needs. The company's focus on this indication comes as it navigates a competitive landscape for its existing multiple myeloma treatment, XPOVIO. Success in securing regulatory approval and commercializing this new combination therapy could significantly alter Karyopharm's growth trajectory.
What we're watching
- Regulatory Approval
- Whether the FDA will accept and grant Priority Review to Karyopharm's planned August sNDA submission for selinexor in combination with ruxolitinib.
- Commercial Performance
- The pace at which Karyopharm can drive increased XPOVIO revenues amidst a competitive multiple myeloma marketplace.
- R&D Progress
- Topline data from the Phase 3 XPORT-MM-031 trial expected in the second half of 2026, which could impact future investment decisions.
Related topics